Evidence map›Paper›PMID 34050898›Full record

ArticleNeurotoxicity research2021

Botulinum Injections for Idiopathic Cervical Dystonia: a Longitudinal Study.

Gilad Yahalom, Tsvia Fay-Karmon, Vered Livneh, Simon Israeli-Korn, Lilach Ephraty, Sharon Hassin-Baer

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gilad YahalomMovement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat-Gan, Israel. gyahalom@gmail.com.
Tsvia Fay-KarmonMovement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Vered LivnehMovement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Simon Israeli-KornMovement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Lilach EphratyMovement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Sharon Hassin-BaerMovement Disorders Institute and Department of Neurology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum toxin (BT) injections into the cervical muscles are an effective and commonly practiced treatment approach for cervical dystonia. In this retrospective longitudinal study, we collected data from the Sheba electronic medical records on consecutive patients with idiopathic cervical dystonia (ICD), treated regularly with periodic BT injections between the years 2008-2020. All treatment visits were analyzed regarding type of toxin, dose injected, and clinical outcomes. The vast majority of patients were treated with abobotulinum toxin A. Sixty-four ICD patients (51 (79.7%) females, onset at age 45.8 ± 13.7 years) were treated over 17.1 ± 13.9 (range 3 to 49) visits per patient; BT treatment efficacy increased gradually from initial treatment sessions to visit 13, when it achieved a steady state. While the subjective report of percentage improvement and its duration were around 78.9 ± 17.1% for 2.8 ± 1.0 months, respectively, the dose of BT increased significantly over the years (p = 0.006). Side effects (SE) were not rare, and commonly recurred after subsequent sessions and were usually mild and short-lasting, with dysphagia being the most common (~17.5%), followed by neck/arm weakness (11.9%) and cervical pain (8.9%). Repeated injections of BT for ICD remain beneficial for patients over several years of therapy, and despite mild SE, patients tend to adhere to a 3-4 months interval schedule.

Indexed as

Acetylcholine Release InhibitorsAdultBotulinum ToxinsCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedRetrospective StudiesTorticollisAcetylcholine Release InhibitorsBotulinum ToxinsBotulinumEffect durationEfficacyLong-term observationSide effects

Identifiers

PMID34050898
OpenAlexW3165639637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.